Phase II Trial of Oral Rubitecan in Previously Treated Pancreatic Cancer Patients

Phase II Trial of Oral Rubitecan in Previously Treated Pancreatic Cancer Patients Howard A. Burris, III, Saul Rivkin, Robert Reynolds, Jules Harris, Arnold Wax, Hal Gerstein, Karl L. Mettinger, Arthur Staddon Oncologist 2005; 10: 183-190 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gastrointestinal cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the current standard of care for the treatment of advanced pancreatic cancer. State the rationale for treating refractory, advanced pancreatic cancer with the novel oral topoisomerase-I inhibitor rubitecan. Describe how the phase II trial results of oral rubitecan in pretreated, advanced pancreatic cancer compare with those from prior trials of rubitecan and gemcitabine in advanced pancreatic cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 25, 2005 Most Recent Review: Mar. 25, 2005* Most Recent Update: Mar. 25, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.